

PERSONAL INFORMATION

Elisabeth Johanne Rook

WORK EXPERIENCE

February 2004–Present

Senior Clinical Assessor

Medicine Evaluation Board (Netherlands)

Clinical assessor in the field of :

Rheumatology- Immunology,

Addiction (abuse potential, alcohol/substance dependence, smoking), Anaesthesiology

PK (including Modeling and Simulation)

EDUCATION AND TRAINING

February 2000–February 2004

PhD

Utrecht University/Slotervaart Hospital Amsterdam (Netherlands)

PhD project/clinical investigator Pk_PD diacetylmorphine in heroin addicted patients

September 1984–May 1991

MD

Utrecht University (Netherlands)

MD

August 1998–September 1999

MSc

EMGO Institute VU Amsterdam (Netherlands)

epidemiology

ADDITIONAL INFORMATION

Expertise

Rheumatology

Clinical Pharmacology (Modeling and Simulation)

Addiction (substance dependence and abuse)

Publications

D. Da Silva, E.Rook, N. Semis-Costa, J. Mueller-Berghaus, R. Vesely, EUROPEAN MEDICINES AGENCY'S GUIDELINE ON THE CLINICAL INVESTIGATION OF MEDICINAL PRODUCTS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS <http://dx.doi.org/10.1136/annrheumdis-2018-eular.6853>

Yvette Weesie, Liset van Dijk, Liesbeth Rook, Lieke Sandberg- Smits, Bert Leufkens, Robert Verheij, Karin Hek Trends in opioid prescribing in Dutch general practice Poster EUROPEAN DRUG UTILISATION RESEARCH GROUP CONFERENCE 2017

E. Rook The Development of A New European Regulatory Guideline on The Clinical Investigation of Medicinal Products for The Treatment of Gout <http://dx.doi.org/10.1136/annrheumdis-2016-eular.6124>

Rook E, REVISION OF EUROPEAN MEDICINE AGENCY'S (EMA) GUIDELINE ON CLINICAL INVESTIGATION OF MEDICINAL PRODUCTS OTHER THAN NSAIDS FOR TREATMENT OF RHEUMATOID ARTHRITIS, <http://dx.doi.org/10.1136/annrheumdis-2016-eular.5721>

A Staab, E Rook, M Maliepaard, L Aarons and C Benson,

Modeling and Simulation in Clinical Pharmacology and

Dose Finding

Pharmacometrics & Systems Pharmacology (2013) 2, e29

Rook EJ, Varenicline (Champix®) geregistreerd, Gebu 2007(mei);41:56-7

Rook EJ, Huitema AD, van den Brink W, van Ree JM, Beijnen JH. Pharmacokinetics and

pharmacokinetic variability of heroin and its metabolites: review of the literature. *Curr Clin Pharmacol*. 2006 Jan;1(1):109-18. Review. PubMed PMID: 18666382.

Rook EJ, Huitema AD, van den Brink W, Hillebrand MJ, van Ree JM, Beijnen JH. Screening for illicit heroin use in patients in a heroin-assisted treatment program. *J Anal Toxicol*. 2006 Jul-Aug;30(6):390-4. PubMed PMID: 16872571.

Rook EJ, van Zanten AP, Van den Brink W, van Ree JM, Beijnen JH. Mast cell mediator tryptase levels after inhalation or intravenous administration of high doses pharmaceutically prepared heroin. *Drug Alcohol Depend*. 2006 Dec 1;85(3):185-90. Epub 2006 Jun 12. PubMed PMID: 16765536.

Rook EJ, Huitema AD, van den Brink W, van Ree JM, Beijnen JH. Population pharmacokinetics of heroin and its major metabolites. *Clin Pharmacokinet*. 2006;45(4):401-17. PubMed PMID: 16584286.

Rook EJ, van Ree JM, van den Brink W, Hillebrand MJ, Huitema AD, Hendriks VM, Beijnen JH. Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid-dependent patients. *Basic Clin Pharmacol Toxicol*. 2006 Jan; 98(1):86-96. PubMed PMID: 16433897.

Rook EJ, Hillebrand MJ, Rosing H, van Ree JM, Beijnen JH. The quantitative analysis of heroin, methadone and their metabolites and the simultaneous detection of cocaine, acetylcodeine and their metabolites in human plasma by high-performance liquid chromatography coupled with tandem mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2005 Sep 25;824(1-2):213-21. PubMed PMID: 16103023.

Projects

Memberships

European Medicines Agency (EMA): COMP (Committee for Orphan Medicinal Products)
EMA: RIWP (Rheumatology Immunology Working Party)

Other Relevant Information